RAD001 Shows Potential To Reverse Resistance To Herceptin(R) In Metastatic Breast Cancer Patients, Leading To Phase III Trial

News — By on December 13, 2008 at 2:00 am

New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab) in women with HER2-positive metastatic breast cancer. These results support the initiation of a Phase III clinical trial program to fully explore the potential of RAD001 (proposed brand name Afinitor(R)) in breast cancer. Two Phase I studies were presented today during the CTRC-AACR San Antonio Breast Cancer Symposium.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback